Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) generates news primarily through its clinical-stage biotechnology activities and corporate transactions. The company has described itself as focused on developing engineered IgM-based therapeutic antibodies, including T cell engaging IgM antibodies, for cancer and autoimmune and inflammatory diseases. Its updates often cover progress in clinical trials, strategic shifts in its pipeline, collaboration developments and significant corporate events.
News items have detailed the advancement of key product candidates such as imvotamab, a CD20 x CD3 bispecific IgM T cell engager antibody studied in autoimmune indications including rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies, and IGM‑2644, a CD38 x CD3 T cell engager antibody in development for autoimmune diseases. Other releases have described clinical studies of aplitabart (also referred to as IGM‑8444), a death receptor 5 agonist evaluated in combination regimens for metastatic colorectal cancer, along with enrollment milestones and trial design features.
Corporate news has included a strategic pivot to focus exclusively on autoimmunity, with an associated pipeline transformation and workforce changes, followed by a later decision to halt further development of imvotamab and IGM‑2644 for autoimmune diseases and to explore internal options and strategic alternatives. IGM Biosciences has also issued announcements about its exclusive worldwide collaboration agreement with Sanofi on IgM antibody agonists for immunology and inflammation targets and other collaborations with biotechnology partners.
A major development in the company’s news flow is the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire IGM Biosciences through a cash tender offer and subsequent merger, with IGM Biosciences becoming a wholly owned subsidiary of Concentra. For readers following IGMS, the news stream provides context on the evolution of the company’s IgM antibody pipeline, its strategic decisions and the transaction that led to its acquisition.
Medivir AB has announced its annual general meeting set for May 4, 2023, in Stockholm, where shareholders can participate in person or via postal voting. Key agenda items include the election of board members, approval of financial reports, and new articles of association. The board proposes a long-term incentive program for key employees, allowing them to receive matching shares based on personal investments. The meeting will also cover proposed share issues and repurchases aimed at funding the incentive program. Shareholders must register by April 25, 2023, to attend or vote.
On March 30, 2023, IGM Biosciences (Nasdaq: IGMS) reported encouraging developments, including the first patient dosed in the IGM-8444 clinical trial for metastatic colorectal cancer. The company aims to advance imvotamab for autoimmune diseases and has initiated a Phase 1 trial for IGM-7354, targeting solid tumors. Financially, IGM reported a net loss of $221.1 million for 2022, with a projected operating expense of $290-$300 million for 2023. Collaboration revenue is expected to reach approximately $3 million. As of December 31, 2022, cash and investments stood at $427.2 million, projected to decrease to $200 million by year-end 2023.
IGM Biosciences (Nasdaq: IGMS) announced its fourth quarter and full year 2022 financial results will be reported on March 30, 2023. A live conference call and webcast will follow at 4:30 p.m. ET, where management will discuss financial outcomes and provide corporate updates. The company is focused on developing engineered IgM antibodies to address cancer, infectious diseases, and autoimmune conditions. IGM has a collaboration with Sanofi for IgM antibody development, enhancing its pipeline's potential. Investors can access the webcast via their website's 'Events and Presentations' section.
Medivir AB (Nasdaq Stockholm: MVIR) announced that it will present data on its leading program, fostroxacitabine bralpamide (fostrox), at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, USA. The presentation, led by CSO Fredrik Öberg, will cover the anti-tumor effects of fostrox combined with an anti-PD1 antibody and a kinase inhibitor. The study suggests that this combination may enhance tumor antigen presentation and immune response, addressing the significant unmet medical need in treating hepatocellular carcinoma (HCC), which accounts for high cancer mortality rates.
Medivir AB (Nasdaq Stockholm: MVIR) announced the initiation of treatment for the first patient with hepatocellular carcinoma (HCC) in the phase 2a trial of fostroxacitabine bralpamide (fostrox) in combination with Lenvima®.
This trial is part of an ongoing multicenter study aimed at patients with HCC who have not responded to or cannot tolerate existing therapies. Preliminary results from the phase 1b study indicate that fostrox has a favorable safety profile. The recommended dose for the combination with Lenvima® has been established at 30 mg, and the study aims to recruit up to 30 patients across clinics in Great Britain, Spain, and South Korea.
Medivir AB (Nasdaq Stockholm: MVIR) will participate in the Stockholm Corporate Finance Life Science Day on March 9, 2023. CEO Jens Lindberg is set to present the company's ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 08:30 CET. The presentation will be accessible on Medivir's website post-event. Medivir focuses on developing innovative cancer treatments addressing significant unmet medical needs, particularly targeting liver cancer cells to minimize side effects. The company collaborates with partners, including IGM Biosciences (Nasdaq: IGMS), for further drug development.
On February 23, 2023, Medivir AB, a pharmaceutical firm focused on cancer treatments, announced its participation in the Erik Penser Bank Healthcare Day. CEO Jens Lindberg will discuss the ongoing clinical study of fostroxacitabine bralpamide (fostrox). The presentation will be accessible on Medivir's website post-event. Medivir aims to address high unmet medical needs in cancer treatment, particularly with fostrox, which targets liver cancer cells while minimizing side effects. Additionally, Medivir collaborates with IGM Biosciences (IGMS) for the development of Birinapant in solid tumor treatments. For more details, visit www.medivir.com.
Medivir AB (MVIR), a pharmaceutical company focused on innovative cancer treatments, announced that Pia Baumann has joined as Chief Medical Officer. She brings extensive oncology experience, previously holding senior roles at AstraZeneca, Takeda, and Incyte. Baumann's expertise will be pivotal as Medivir advances its drug candidate, fostroxacitabine bralpamide (fostrox), into the expansion phase (phase 2a) in combination with Lenvima®. Medivir aims to address high unmet medical needs in cancer therapy, particularly targeting liver cancer cells with minimal side effects.
Medivir AB (Nasdaq Stockholm: MVIR) has successfully completed the initial dose escalation part (phase 1b) of its study on fostroxacitabine bralpamide (fostrox) for hepatocellular carcinoma (HCC) in combination with Lenvima®. Preliminary results indicate a positive safety and tolerability profile, with no dose-limiting toxicity reported. The recommended dose for the phase 2a study has been set at 30 mg. The trial aims to evaluate the efficacy of fostrox in patients unresponsive to first-line treatments. Further recruitment for the phase 2a part will involve up to 30 patients across 14 clinics in the UK, Spain, and South Korea.
MOUNTAIN VIEW, Calif., Feb. 2, 2023 – IGM Biosciences (Nasdaq: IGMS) announced that CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on February 9, 2023, at 1:35 p.m. EST in New York. A live webcast will be available on the Company’s website, and a replay will be archived for 30 days post-event.
IGM Biosciences specializes in engineered IgM antibodies for treating cancer and other diseases. The Company collaborates with Sanofi to develop IgM antibody agonists targeting oncology and immunology. For more details, visit www.igmbio.com.